Shunji Kamigaki

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

Norikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita et al. · The Lancet Oncology · 2012 · 175 citations

Breast Oncology, Medicine, Pharmacology +9

Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population

Masakazu Toi, Hiroji Iwata, Takeharu Yamanaka et al. · Cancer · 2010 · 112 citations · Full text

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

Shinji Ohno, Y. Rai, Hiroji Iwata et al. · Annals of Oncology · 2010 · 72 citations

Advanced Breast Cancer, Breast Oncology, Medicine +11

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Shinji Ohno, Louis W.C. Chow, Nobuaki Sato et al. · Breast Cancer Research and Treatment · 2013 · 55 citations · Full text

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

Kenjiro Aogi, Norikazu Masuda, Shinji Ohno et al. · Breast Cancer Research and Treatment · 2011 · 43 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +8